In patients with multiple myeloma, only two potential neoantigens, UBR4 and PRKDC, were detected in both relapsed and newly diagnosed patients.41 Therefore, the SNV neoantigens landscape is highly variable between different cancer types and different stages of the same cancer type (Table 2). This evidence concerns the gene PRKDC and cancer.